Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma

The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.